000 01373 a2200385 4500
005 20250518043700.0
264 0 _c20191021
008 201910s 0 0 eng d
022 _a1314-2143
024 7 _a10.2478/folmed-2018-0030
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLinev, Alexandar J
245 0 0 _aMutations Associated with Imatinib Mesylate Resistance - Review.
_h[electronic resource]
260 _bFolia medica
_cDec 2018
300 _a617-623 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAmino Acid Substitution
650 0 4 _aAntineoplastic Agents
_xpharmacology
650 0 4 _aDrug Resistance, Neoplasm
_xgenetics
650 0 4 _aFusion Proteins, bcr-abl
_xchemistry
650 0 4 _aHumans
650 0 4 _aImatinib Mesylate
_xpharmacology
650 0 4 _aLeukemia, Myelogenous, Chronic, BCR-ABL Positive
_xdrug therapy
650 0 4 _aModels, Molecular
650 0 4 _aPoint Mutation
650 0 4 _aProtein Domains
650 0 4 _aProtein Kinase Inhibitors
_xpharmacology
700 1 _aIvanov, Hristo J
700 1 _aZhelyazkov, Ivan G
700 1 _aIvanova, Hristina
700 1 _aGoranova-Marinova, Veselina S
700 1 _aStoyanova, Vili K
773 0 _tFolia medica
_gvol. 60
_gno. 4
_gp. 617-623
856 4 0 _uhttps://doi.org/10.2478/folmed-2018-0030
_zAvailable from publisher's website
999 _c29788323
_d29788323